Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.

ABSTRACT:

Background and aim

The use of biologics and small molecules has been a concern for patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic. We aimed to assess the association between the risk of COVID-19-related hospitalization and these agents.

Methods

We made a systematic review and meta-analysis of all published studies from December 2019 to September 2021 to identify studies that reported COVID-19-related hospitalization in IBD patients receiving biologic therapies or tofacitinib. We calculated the risk ratio (RR) to compare the relative risk of COVID-19-related hospitalization in patients receiving these medications to those who were not, at the time of the study.

Results

Eighteen studies were included. The relative risk of hospitalization was

SUBMITTER: Alrashed F 

PROVIDER: S-EPMC9021715 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature